Sign in
Not yet taking people in United StatesPhase 2

A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC

Key facts

Who runs it
AstraZeneca
Where
Atlanta, Golden, Greer, Irvine, Miami, Morgantown, New Haven, Oakland, Peoria, Salt Lake City, Sugar Land, and Tampa, United StatesSee the 12 sitesAlso in 10 other countries, 61 sites
Status
Not yet recruiting
Phase
Phase 2
People taking part
250 people, planned
Starts
30 Nov 2026
Expected to end
22 Dec 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Dato-DXd
  • Durvalumab
  • Carboplatin
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 44 criteriaShow less

Who can take part

  • Participant must be ≥ 18 years of age at the time of signing the ICF
  • Pathologically documented NSCLC that:; Has documented non-squamous histology; Is TROP2 NMR positive; Documented lack of sensitising EGFR mutation, as well as ALK and ROS1 rearrangements on tumour tissue
  • Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation, or Stage IV metastatic NSCLC at the time of randomisation, as per the American Joint Committee on Cancer Staging System, 9th Edition
  • The ECOG PS of 0 to 2
  • Known tumour PD-L1 status
  • Minimum life expectancy of 12 weeks
  • Provision of acceptable FFPE tumour sample from a lesion not previously irradiated
  • At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline
  • Adequate bone marrow reserve and organ function
  • Contraceptive use by participants or participant partners
  • Capable of giving signed informed consent
  • Provision of signed and dated optional informed consent

Who cannot take part

  • As judged by the investigator, any evidence of diseases, chronic diverticulitis or previous complicated diverticulitis, or history of allogenic organ transplant, which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol
  • History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, lentigo maligna that has undergone potentially curative therapy, or adequately treated in situ disease without evidence of disease
  • Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia or vitiligo, not yet improved to Grade ≤ 1 or baseline
  • Active or prior documented autoimmune, connective tissue or inflammatory disorders, autoimmune pneumonitis, or autoimmune myocarditis
  • Spinal cord compression or CNS metastases, unless asymptomatic, stable, and not requiring treatment with corticosteroids or anticonvulsants for at least 7 days prior to randomisation
  • Prior exposure to:; Any agent, including ADC, containing a chemotherapeutic agent targeting topoisomerase I; Chemotherapy or any other systemic therapy for first-line Stage IIIB, IIIC, or IV NSCLC; TROP2-targeted therapy; Chloroquine/hydroxychloroquine without an adequate treatment washout period
  • Participants who have received any prior adjuvant, neoadjuvant, or definitive chemoradiation for early stage disease (Stage I to III) are eligible, provided they meet the protocol-defined conditions
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention
  • Any concurrent anti-cancer treatment
  • Any concomitant medication known to be associated with Torsades de Pointes
  • Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention
  • Received prior radiotherapy to the brain within 2 weeks of start of study intervention or received palliative radiotherapy to the chest within 4 weeks of start of study intervention or has ongoing radiation-related toxicities requiring corticosteroids
  • Major surgical procedure or significant traumatic injury within ≤ 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study
  • Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to randomisation or concurrent participation in another clinical study
  • History of leptomeningeal carcinomatosis or metastasis
  • Clinically significant corneal disease
  • Has active or uncontrolled HBV or HCV infection
  • Known HIV infection that is not well controlled
  • Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections
  • Known to have active tuberculosis infection
  • Uncontrolled or significant cardiac disease
  • History of ILD/pneumonitis
  • Participants with a known history of severe hypersensitivity reactions to study intervention or any excipients of these products
  • Participants with a known history of severe hypersensitivity reactions to other monoclonal antibodies
  • Has documented tumour genomic alterations in EGFR, ALK, ROS1, NTRK, BRAF V600E, RET, MET exon 14, or any other actionable driver oncogenes for which there are locally approved and available targeted first-line therapies; Note: Participants whose tumours harbour KRAS mutations are eligible for the study
  • For females only: Is pregnant (confirmed with positive serum pregnancy test), or breastfeeding, or planning to become pregnant
  • Squamous histology or mixed SCLC and NSCLC, or sarcomatoid variant of NSCLC, or lung neuroendocrine tumours
  • Mean resting QTcF > 470 ms, regardless of gender, obtained from triplicate 12-lead ECGs performed at screening
  • Has clinically severe pulmonary function compromised
  • Allocation to a stratum that has reached the cap
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements

Where in United States

Also in 10 other countries, 61 sites

  • Atlanta, GeorgiaHospital not named in the registryNot yet recruiting
  • Golden, ColoradoHospital not named in the registryNot yet recruiting
  • Greer, South CarolinaHospital not named in the registryNot yet recruiting
  • Irvine, CaliforniaHospital not named in the registryNot yet recruiting
  • Miami, FloridaHospital not named in the registryNot yet recruiting
  • Morgantown, West VirginiaHospital not named in the registryNot yet recruiting
  • New Haven, ConnecticutHospital not named in the registryNot yet recruiting
  • Oakland, CaliforniaHospital not named in the registryNot yet recruiting
  • Peoria, IllinoisHospital not named in the registryNot yet recruiting
  • Salt Lake City, UtahHospital not named in the registryNot yet recruiting
  • Sugar Land, TexasHospital not named in the registryNot yet recruiting
  • Tampa, FloridaHospital not named in the registryNot yet recruiting

About the trial

What the trial wants to find out

Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.

The 2 groups in the trial

  • Treatment ATreatment being tested

    Participants will receive Dato-DXd and durvalumab Q3W on Day 1 of every 21-day cycle.

    Treatment: Dato-DXd and Durvalumab

  • Treatment BTreatment being tested

    Participants will receive Dato-DXd, durvalumab, and carboplatin Q3W on Day 1 of every 21-day cycle for the first 4 cycles, followed by Dato-Dxd and durvalumab Q3W

    Treatment: Dato-DXd, Durvalumab, and Carboplatin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-Based Combinations in Adult Participants With TROP2 NMR-positive Non-small Cell Lung Cancer (NSCLC) (PATAGONIA)
Record updated
17 November 2026